The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
 
Michael Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Research Funding - Jonathon David Foundation; National Cancer Institute; Veterans Affairs
Patents, Royalties, Other Intellectual Property - Novartis (Inst)
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
Travel, Accommodations, Expenses - NewBay Pharma
 
Robin Jones
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
César Serrano
Honoraria - Deciphera; Roche
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; NewBay Pharma
Research Funding - IDRX (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Boehringer Ingelheim; Deciphera; Ipsen; Replimune
Research Funding - Advenc (Inst); Ascentage Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Karyopharm Therapeutics (Inst)
 
Hans Gelderblom
Research Funding - Abbisko (Inst); AmMax Bio (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); SynOX (Inst)
 
John Zalcberg
Leadership - ICON Group; Lipotek; Praxis Therapeutics
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; CSL Limited; CSL Limited; Frequency Therapeutics; Gilead Sciences; Korro; Moderna Therapeutics; Novavax; Opthea; Orphazyme; UniQure
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Avance Clinical; BioIntelect; BioNTech SE; Deciphera; Duo Oncology; FivePHusion; Genor BioPharma; Merck Sharp & Dohme; Oncology Republic; Revolution Medicines; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst); Servier (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - ICON Group; MSD Oncology; Praxis Therapeutics
 
William Reichmann
Employment - Deciphera
 
Kam Sprott
Employment - Deciphera; Stablix (I)
Stock and Other Ownership Interests - Stablix (I)
 
Matthew Sherman
Employment - Deciphera
Leadership - Deciphera
Patents, Royalties, Other Intellectual Property - Deciphera
Travel, Accommodations, Expenses - Deciphera
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; IDRX; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories (I); Pfizer (I)
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Acrivon Therapeutics (Inst); BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); NewBay Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
on behalf of the INSIGHT study investigators
No Relationships to Disclose